FDA CONSUMER HEALTH INFORMATION - FDA's MedWatch Safety Alerts: September 2011

SILVER SPRING, Md., Oct. 6, 2011 /PRNewswire-USNewswire/ -- The Food and Drug Administration (FDA) has recently issued safety alerts about a number of products, including

  • recalled birth control pills because of a packaging error
  • an antipsychotic drug that can cause serious allergic reactions
  • a drug infusion pump with battery problems
  • an osteoporosis drug with a risk of severe kidney problems

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

These and other alerts were prompted by reports FDA received from health care professionals and the public through the agency's MedWatch Adverse Event Reporting Program.

Learn more about these safety alerts and what to do if you've used one of the products described here.
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm274455.htm

Sign up for e-mail notices of new FDA Consumer Updates at
https://service.govdelivery.com/service/subscribe.html?code=USFDA_9

View the FDA Consumer Update RSS feed at http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/RSSFeeds/Consumers/rss.xml

FDA Consumer Updates may be posted and published elsewhere without permission. Please credit "FDA Consumer Health Information (www.fda.gov/consumer)" as the source. FDA values feedback on its consumer health information. Send questions, comments, or story ideas to: [email protected].

Media Contact: Jason Brodsky, 301-796-8234, [email protected]

SOURCE U.S. Food and Drug Administration

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.